Boston, MA 08/14/2014 (wallstreetpr) – Horizon Pharma Inc (NASDAQ:HZNP) has announced that POZEN Inc. (NASDAQ:POZN) has got the notice of allowance from the US Patent and Trademark Office. It is related with the patent application number 14/045,156. It is under the title “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs” The notice of allowance is related with VIMOVO® delayed release tablets. It is the US approved product of POZEN and Horizon.
The notice
The Notice of Allowance includes the claims that state the expansion of the strength of its VIMOVO patent estate. It provides Horizon with the power to protect VIMOVO innovation. It is a significant form of therapy treatment for patients. It ends the meaningful review of the patent application. Once the administrative processes get over, the company can get the issuance of US patent. It will be valid till 2022. Horizon Pharma Inc (NASDAQ:HZNP) further aims to list the US patent in the Orange Book.
The earnings beat
Horizon Pharma Inc (NASDAQ:HZNP) also reported the strong results in the last week. The revenues saw a sharp jump of 495% year-over-year. The revenues came at $66.1 million in second-quarter. It was ahead of the analysts’ expectation of $60.2 million. Net Income came at $20.7 million. It accounts for earnings of $0.21 per share, beating the analysts’ expectation of $0.135 per share.
The major source of revenues
Any form of development in its products, VIMOVO, RAYOS and DUEXIS is significant for Horizon Pharma Inc (NASDAQ:HZNP). These three products form the major source of revenues for the company. VIMOVO is an arthritis pain reliever. It contributed $42.4 million of the sales in the second-quarter. The contribution of RAYOS and DUEXIS stands at $3.9 million and $17.8 million respectively. Horizon has plans to add Actimmune in its product portfolio. It can add the same once it completes the acquisition of Vidara Therapeutics in this September.
